Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria, especially Bacteroides fragilis. Clindamycin is also used to treat infections caused by Gram-positive infections such as Streptococci, Staphylococci (including methicillin-resistant strains ) and Pneumococci. Because of the risk of colitis, cclindamycin is not the first drug of choice and should only be selected when there is no suitable alternative therapy.
Clindamycin is also indicated in the treatment of infections due to susceptible strains n the following cases: Ear, nose and throat infections caused by penicilin resistant S.pneumoniae, bronchitis, dental infection, skin infections, acne, genital tract infections, osteoarthritis, sepsis (except meningitis). Intra-abdominal infections such as peritonitis and intra-abdominal abscess; festering wound infections (surgery or trauma), infections of the female pelvis and genital tract such as endometritis, nongonococcal tuboovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection by anaerobic bacteria.
The prophylaxis of bacterial endocarditis in patients allergic to penicillin before dental, respiratory tract surgery. In addition, clindamycin also combined with quinine for oral administration to treat cloroquin-resistant malaria; with primaquin to treat pneumonia caused by Pneumocystin jiroveci; with pyrimethamin for the treatment of Toxoplasma.
Multidrug regimen for the treatment of anthrax caused by inhalation of anthrax spores, severe skin anthrax.

This is only the preview. Please check here for the full indication.